X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (19) 19
index medicus (19) 19
hematology, oncology and palliative medicine (12) 12
multiple myeloma (12) 12
oncology (12) 12
female (10) 10
aged (9) 9
bortezomib (9) 9
multiple myeloma - drug therapy (9) 9
male (8) 8
adult (7) 7
cancer (7) 7
middle aged (7) 7
chemotherapy (6) 6
further section · weitere sektionen (6) 6
hematology (6) 6
antineoplastic combined chemotherapy protocols - therapeutic use (5) 5
prognosis (5) 5
survival (5) 5
transplants & implants (5) 5
treatment outcome (5) 5
bone marrow (4) 4
care and treatment (4) 4
clinical trials (4) 4
dexamethasone (4) 4
dexamethasone - administration & dosage (4) 4
disease-free survival (4) 4
follow-up studies (4) 4
lenalidomide (4) 4
medical colleges (4) 4
neoplasm recurrence, local - drug therapy (4) 4
patients (4) 4
proteasome inhibitors (4) 4
proteins (4) 4
stem-cell transplantation (4) 4
therapy (4) 4
antineoplastic agents - adverse effects (3) 3
antineoplastic combined chemotherapy protocols - adverse effects (3) 3
bortezomib - adverse effects (3) 3
diagnosis (3) 3
drug administration schedule (3) 3
drug resistance, neoplasm - drug effects (3) 3
expression (3) 3
hemic and lymphatic diseases (3) 3
incidence (3) 3
medicine (3) 3
melphalan (3) 3
multiple myeloma - mortality (3) 3
multiple myeloma - pathology (3) 3
multiple-myeloma (3) 3
neoplasm recurrence, local - mortality (3) 3
neoplasm recurrence, local - pathology (3) 3
neoplasm staging (3) 3
peripheral neuropathy (3) 3
product development (3) 3
risk factors (3) 3
survival analysis (3) 3
survival rate (3) 3
thalidomide - analogs & derivatives (3) 3
toxicity (3) 3
transplantation (3) 3
administration, oral (2) 2
aged, 80 and over (2) 2
animals (2) 2
boronic acids - administration & dosage (2) 2
boronic acids - adverse effects (2) 2
bortezomib - pharmacology (2) 2
carcinoma (2) 2
cell growth (2) 2
cell lines (2) 2
cell proliferation (2) 2
cell survival (2) 2
chromatin (2) 2
consensus (2) 2
cyclophosphamide (2) 2
dexamethasone - adverse effects (2) 2
dexamethasone - therapeutic use (2) 2
diseases (2) 2
dna (2) 2
dose-response relationship, drug (2) 2
double-blind method (2) 2
drug dosages (2) 2
end-points (2) 2
genetic research (2) 2
genetics & heredity (2) 2
infusions, intravenous (2) 2
kaplan-meier estimate (2) 2
lbh589 (2) 2
lenalidomide plus dexamethasone (2) 2
leukemia (2) 2
leukocytes, mononuclear - drug effects (2) 2
melphalan - adverse effects (2) 2
motivation (2) 2
multiparameter flow-cytometry (2) 2
nucleotide excision-repair (2) 2
oligopeptides - adverse effects (2) 2
oligopeptides - pharmacology (2) 2
ovarian cancer (2) 2
ovarian neoplasms - pathology (2) 2
peripheral nervous system diseases - chemically induced (2) 2
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Oncology, The, ISSN 1470-2045, 2014, Volume 15, Issue 12, pp. e538 - e548
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 1, pp. 27 - 38
Journal Article
Journal Article
Journal Article
Lancet Haematology, The, ISSN 2352-3026, 2016, Volume 3, Issue 11, pp. e506 - e515
Summary Background Panobinostat plus bortezomib and dexamethasone significantly increased median progression-free survival compared with placebo plus... 
Hematology, Oncology and Palliative Medicine | MULTICENTER | LBH589 | LENALIDOMIDE | END-POINTS | RISK | OUTCOMES | COMBINATION | HEMATOLOGY | Peripheral Nervous System Diseases - chemically induced | Humans | Middle Aged | Dexamethasone - adverse effects | Male | Fatigue - chemically induced | Multiple Myeloma - ethnology | Bortezomib - pharmacology | Dexamethasone - pharmacology | Time Factors | Renal Insufficiency - complications | Panobinostat | Patient Dropouts - statistics & numerical data | Thrombocytopenia - chemically induced | Disease Progression | Antineoplastic Agents, Alkylating - therapeutic use | Dexamethasone - therapeutic use | Geography - statistics & numerical data | Indoles - adverse effects | Bortezomib - therapeutic use | Bortezomib - adverse effects | Survival Analysis | Creatinine - blood | Quality of Life | Hydroxamic Acids - therapeutic use | Indoles - therapeutic use | Age Factors | Multiple Myeloma - mortality | Hydroxamic Acids - adverse effects | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Neoplasm Recurrence, Local - drug therapy | Diarrhea - chemically induced | Neoplasm Recurrence, Local - mortality | Antineoplastic Combined Chemotherapy Protocols - pharmacology | Multiple Myeloma - drug therapy | Chromosome Aberrations - statistics & numerical data | Chromosome Aberrations - drug effects | Adult | Female | Indoles - pharmacology | Steroids - therapeutic use | Hydroxamic Acids - pharmacology | Double-Blind Method | Blood Cell Count - statistics & numerical data | Multiple Myeloma - complications | Hematopoietic Stem Cell Transplantation - statistics & numerical data | Treatment Outcome | Asthenia - chemically induced | Hydroxamic Acids - pharmacokinetics | Asian Continental Ancestry Group - ethnology | Disease-Free Survival | Activities of Daily Living - classification | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Sex Factors | Indoles - pharmacokinetics | Aged | Neoplasm Staging | Bortezomib - pharmacokinetics | Drug Resistance, Neoplasm - drug effects | Immunologic Factors - therapeutic use
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2017, Volume 18, Issue 2, pp. 241 - 250
Journal Article
by Dimopoulos, Meletios A and Dimopoulos, Athanasios and Gay, Francesca and Schjesvold, Fredrik and Beksac, Meral and Hajek, Roman and Weisel, Katja Christina and Weisel, Katja and Goldschmidt, Hartmut and Maisnar, Vladimir and Moreau, Philippe and Min, Chang Ki and Pluta, Andrzej and Pluta, Agnieszka and Chng, Wee Joo and Chng, Wee-Joo and Kaiser, Martin and Zweegman, Sonja and Mateos, Maria-Victoria and Mateos, Maria Victoria and Spencer, Andrew and Iida, Shinsuke and Morgan, Gareth and Suryanarayan, Kaveri and Teng, Zhaoyang and Skacel, Tomas and Palumbo, Antonio and Dash, Ajeeta B and Gupta, Neeraj and Labotka, Richard and Rajkumar, S Vincent and Bar, Daniel and Basso, Alfredo and Fantl, Dorotea and He, Simon and Horvath, Neomi and Lee, Cindy and Lee, Jae Hoon and Rowlings, Phillip and Taylor, Kerry and Cochrane, Tara and Kwok, Fiona and Ramanathan, Sundreswran and Agis, Hermine and Zojer, Niklas and Kentos, Alain and Offner, Fritz and Van Droogenbroeck, Jan and Wu, Ka Lung and Maiolino, Angelo and Martinez, Gracia and Zanella, Karla and Capra, Marcelo and Araújo, Sérgio and Gregora, Evzen and Pour, Ludek and Scudla, Vlastimil and Spicka, Ivan and Abildgaard, Niels and Andersen, Niels and Jensen, Bo Amdi and Helleberg, Carsten and Plesner, Torben and Salomo, Morten and Svirskaite, Asta and Delarue, Richard and Blau, Igor and Schieferdecker, Aneta and Teleanu, Veronica and Munder, Markus and Röllig, Christoph and Salwender, Han-Juergen and Fuhrmann, Stephan and Duerig, Jan and Zeis, Matthias and Klein, Stefan and Reimer, Peter and Schmidt, Christian and Scheid, Christof and Mayer, Karin and Hoffmann, Martin and Sosada, Markus and Delimpasi, Sosana and Kyrtsonis, Mary-Christine and Anagnostopoulos, Achilleas and Nagy, Zsolt and Illés, Árpád and Egyed, Miklós and Borbényi, Zita and Mikala, Gabor and Dally, Najib and Horowitz, Netanel and Gutwein, Odit and Nemets, Anatoly and Vaxman, Iuliana and Shvetz, Olga and Trestman, Svetlana and Ruchlemer, Rosa and Nagler, Arnon and Tadmor, Tamar and ... and TOURMALINE-MM3 Study Grp and TOURMALINE-MM3 study group
The Lancet, ISSN 0140-6736, 01/2019, Volume 393, Issue 10168, pp. 253 - 264
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 8, pp. e328 - e346
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2014, Volume 15, Issue 11, pp. 1195 - 1206
Journal Article